ACE2 and COVID-19: αvβ6 integrin has been reported to be of interest in inhibiting SARS-CoV-2 entry and treating coronavirus disease 2019 (COVID-19)-related diseases.447 SARS-CoV-2 acts on human cells through angiotensin converting enzyme II (ACE2), and recent studies suggested that integrins might be the cell receptors for SARS-CoV-2.448 The association between the S protein of SARS-CoV-2 and the ACE2 receptor has been established, but the S1 subunit contains a solvent-exposed RGD-binding motif.